Press Releases

Date Title and Summary Additional Formats
Toggle Summary Conatus Pharmaceuticals Announces Presentations and Posters at AASLD Annual Meeting
SAN DIEGO , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today the schedule of upcoming oral presentations and posters addressing clinical and preclinical results with the company’s pan-caspase inhibitor emricasan, or addressing preclinical results with
View HTML
Toggle Summary Conatus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Program Updates
SAN DIEGO , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the quarter and nine months ended September 30, 2018 ,
View HTML
Toggle Summary Conatus Pharmaceuticals to Report Third Quarter 2018 Financial Results
SAN DIEGO , Oct. 25, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the third quarter ended September 30, 2018 , after the market close on Thursday, November 1, 2018 . Conatus will host a conference call and audio
View HTML
Toggle Summary Conatus Pharmaceuticals Announces Three Accepted Abstracts for AASLD Annual Meeting
SAN DIEGO , Oct. 02, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today that two abstracts – one addressing clinical results with the company’s pan-caspase inhibitor, emricasan, and one addressing preclinical results with the company’s pan-caspase inhibitor,
View HTML
Toggle Summary Conatus Pharmaceuticals to Host Analyst and Investor Symposium on Portal Hypertension
SAN DIEGO , Sept. 20, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development of novel medicines to treat liver disease, will host an invitation-only symposium on portal hypertension for institutional investors and research analysts on
View HTML
Toggle Summary Conatus Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO , Sept. 19, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has accepted invitations to participate in two upcoming investor conferences. At the Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease ( September 26-27 in New York ), senior management will
View HTML
Toggle Summary Conatus Pharmaceuticals to Present at BioCentury NewsMakers Conference
SAN DIEGO , Aug. 29, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it has been invited to present at the BioCentury 25 th Annual NewsMakers
View HTML
Toggle Summary Conatus Pharmaceuticals Reports Second Quarter 2018 Financial Results and Program Updates
SAN DIEGO , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the quarter and six months ended June 30, 2018 , and
View HTML
Toggle Summary Conatus Pharmaceuticals to Report Second Quarter 2018 Financial Results
SAN DIEGO , July 25, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the second quarter ended June 30, 2018 , after the market close on Wednesday, August 1, 2018 . Conatus will host a conference call and audio webcast at
View HTML
Toggle Summary Conatus Pharmaceuticals’ Pan-caspase Inhibitor Emricasan Improves Survival and Portal Hypertension in a Mouse Model of Cirrhosis
SAN DIEGO , July 02, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the publication 1 of results from preclinical studies of its pan-caspase inhibitor emricasan, demonstrating improvements in portal hypertension (elevated blood pressure in the vein flowing into
View HTML